{'fraction_non_alphanumeric': 0.013020833333333334, 'fraction_numerical': 0.0026041666666666665, 'mean_word_length': 5.30327868852459, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Development of psoriasis 10 years after allogeneic hematopoietic cell transplantation from non‐psoriatic donor: Further evidences for genetics and immunopathogenesis of psoriasis

Japan and only five instances from other countries. This scarcity of papers on adalimumab for GPP highlights the significance of our report. The case we experienced was rare in that GPP developed in a PsA patient, who refused infusion. Adalimumab elicited a favorable response to the concomitant GPP. No similar reports have been published except for a case reported by Zangrilli et al. More case records should be collected to establish evidence that adalimumab is a safe and effective treatment, even for GPP patients judged as having primary or secondary failure to infliximab therapy.